U
The startup develops pharmaceutical compounds that utilize IAP-dependent protein erasers for targeted protein degradation, specifically focusing on overexpressed proteins in tumor cells. This approach aims to address the need for effective treatments in cancer and other unmet medical conditions through targeted proteolysis inducers.
Tokyo, Japan
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops pharmaceutical compounds that utilize IAP-dependent protein erasers for targeted protein degradation, specifically focusing on overexpressed proteins in tumor cells. This approach aims to address the need for effective treatments in cancer and other unmet medical conditions through targeted proteolysis inducers.